Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Abstract: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combinatio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236019727663104 |
|---|---|
| author | Andrew J. Yee Jacob P. Laubach Erica L. Campagnaro Brea C. Lipe Omar Nadeem Robb S. Friedman Craig E. Cole Elizabeth K. O’Donnell Giada Bianchi Andrew R. Branagan Robert L. Schlossman Samantha J. Shapiro Cynthia C. Harrington Jill N. Burke Marilyn T. Gammon Kathleen J. Lively Cassandra A. Reimonn Danielle X. Andrade Robert Redd Jens G. Lohr Kenneth C. Anderson Paul G. Richardson Noopur S. Raje |
| author_facet | Andrew J. Yee Jacob P. Laubach Erica L. Campagnaro Brea C. Lipe Omar Nadeem Robb S. Friedman Craig E. Cole Elizabeth K. O’Donnell Giada Bianchi Andrew R. Branagan Robert L. Schlossman Samantha J. Shapiro Cynthia C. Harrington Jill N. Burke Marilyn T. Gammon Kathleen J. Lively Cassandra A. Reimonn Danielle X. Andrade Robert Redd Jens G. Lohr Kenneth C. Anderson Paul G. Richardson Noopur S. Raje |
| author_sort | Andrew J. Yee |
| collection | DOAJ |
| description | Abstract: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory MM. Therefore, we studied adding elotuzumab to PVd (elo-PVd) in relapsed/refractory MM in a multicenter phase 2 trial. The primary objective was to determine the overall response rate (ORR). Patients with relapsed/refractory disease and ≥1 prior line of treatment (including lenalidomide and a proteasome inhibitor) were eligible. For each 28-day cycle, elotuzumab was weekly for the first 2 cycles and then every other week; pomalidomide on days 1 to 21; bortezomib on days 1, 8, and 15; and dexamethasone weekly. The trial enrolled 48 patients with a median 3 prior lines (range, 1-9). Prior therapies included pomalidomide (33%), daratumumab (25%), and isatuximab (4%). The ORR was 56.3%, and the median progression-free survival (PFS) was 10 months. In patients with 1 prior line of therapy, ORR was 73.7%; median PFS was 23.4 months. Common grade ≥3 adverse events were neutropenia (33%); infections, any (33%); lung infection (27%); hypophosphatemia (19%); and thrombocytopenia (15%). Elo-PVd is, to our knowledge, one of the first trials of a quadruplet regimen in relapsed/refractory MM incorporating a monoclonal antibody to show efficacy across diverse prior treatments, including triple-class exposed patients with prior anti-CD38 monoclonal antibody. This trial was registered at ClinicalTrials.gov as #NCT02718833. |
| format | Article |
| id | doaj-art-7a04ed1752b14aef9c20c4275fedcdf2 |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-7a04ed1752b14aef9c20c4275fedcdf22025-08-20T02:02:05ZengElsevierBlood Advances2473-95292025-03-01951163117010.1182/bloodadvances.2024014717Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J. Yee0Jacob P. Laubach1Erica L. Campagnaro2Brea C. Lipe3Omar Nadeem4Robb S. Friedman5Craig E. Cole6Elizabeth K. O’Donnell7Giada Bianchi8Andrew R. Branagan9Robert L. Schlossman10Samantha J. Shapiro11Cynthia C. Harrington12Jill N. Burke13Marilyn T. Gammon14Kathleen J. Lively15Cassandra A. Reimonn16Danielle X. Andrade17Robert Redd18Jens G. Lohr19Kenneth C. Anderson20Paul G. Richardson21Noopur S. Raje22Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MADivision of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MIDepartment of Hematology/Oncology, University of Rochester, Rochester, NYDana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MANewton-Wellesley Hospital, Newton, MADivision of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MICenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MADana-Farber Cancer Institute, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MADana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; Harvard Medical School, Boston, MA; Correspondence: Noopur S. Raje, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114;Abstract: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory MM. Therefore, we studied adding elotuzumab to PVd (elo-PVd) in relapsed/refractory MM in a multicenter phase 2 trial. The primary objective was to determine the overall response rate (ORR). Patients with relapsed/refractory disease and ≥1 prior line of treatment (including lenalidomide and a proteasome inhibitor) were eligible. For each 28-day cycle, elotuzumab was weekly for the first 2 cycles and then every other week; pomalidomide on days 1 to 21; bortezomib on days 1, 8, and 15; and dexamethasone weekly. The trial enrolled 48 patients with a median 3 prior lines (range, 1-9). Prior therapies included pomalidomide (33%), daratumumab (25%), and isatuximab (4%). The ORR was 56.3%, and the median progression-free survival (PFS) was 10 months. In patients with 1 prior line of therapy, ORR was 73.7%; median PFS was 23.4 months. Common grade ≥3 adverse events were neutropenia (33%); infections, any (33%); lung infection (27%); hypophosphatemia (19%); and thrombocytopenia (15%). Elo-PVd is, to our knowledge, one of the first trials of a quadruplet regimen in relapsed/refractory MM incorporating a monoclonal antibody to show efficacy across diverse prior treatments, including triple-class exposed patients with prior anti-CD38 monoclonal antibody. This trial was registered at ClinicalTrials.gov as #NCT02718833.http://www.sciencedirect.com/science/article/pii/S2473952924006943 |
| spellingShingle | Andrew J. Yee Jacob P. Laubach Erica L. Campagnaro Brea C. Lipe Omar Nadeem Robb S. Friedman Craig E. Cole Elizabeth K. O’Donnell Giada Bianchi Andrew R. Branagan Robert L. Schlossman Samantha J. Shapiro Cynthia C. Harrington Jill N. Burke Marilyn T. Gammon Kathleen J. Lively Cassandra A. Reimonn Danielle X. Andrade Robert Redd Jens G. Lohr Kenneth C. Anderson Paul G. Richardson Noopur S. Raje Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma Blood Advances |
| title | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma |
| title_full | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma |
| title_fullStr | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma |
| title_full_unstemmed | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma |
| title_short | Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma |
| title_sort | elotuzumab in combination with pomalidomide bortezomib and dexamethasone in relapsed and refractory multiple myeloma |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924006943 |
| work_keys_str_mv | AT andrewjyee elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT jacobplaubach elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT ericalcampagnaro elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT breaclipe elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT omarnadeem elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT robbsfriedman elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT craigecole elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT elizabethkodonnell elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT giadabianchi elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT andrewrbranagan elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT robertlschlossman elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT samanthajshapiro elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT cynthiacharrington elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT jillnburke elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT marilyntgammon elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT kathleenjlively elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT cassandraareimonn elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT daniellexandrade elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT robertredd elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT jensglohr elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT kennethcanderson elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT paulgrichardson elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma AT noopursraje elotuzumabincombinationwithpomalidomidebortezomibanddexamethasoneinrelapsedandrefractorymultiplemyeloma |